ReviewCytotherapy2014
Engineered T cells for cancer treatment.
Review in Cytotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Beyond lymphopenia, unraveling radiation-induced leucocyte subpopulation kinetics and mechanisms through modeling approaches.Journal of experimental & clinical cancer research : CR · 2023Review
- T Cell Microvilli: Finger-Shaped External Structures Linked to the Fate of T Cells.Immune network · 2023Review
- In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes.PLoS computational biology · 2022Article
- Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.Molecular therapy oncolytics · 2020Article
- Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy.Translational oncology · 2020Review
- Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Advancing Immune and Cell-Based Therapies Through Imaging.Molecular imaging and biology · 2017Review
- Towards a commercial process for the manufacture of genetically modified T cells for therapy.Cancer gene therapy · 2015Review
- Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.Molecular cancer · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.